Literature DB >> 30266715

Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors.

Ajit J Nirmal1, Tim Regan1, Barbara B Shih1, David A Hume1,2, Andrew H Sims3, Tom C Freeman4.   

Abstract

The immune composition of the tumor microenvironment regulates processes including angiogenesis, metastasis, and the response to drugs or immunotherapy. To facilitate the characterization of the immune component of tumors from transcriptomics data, a number of immune cell transcriptome signatures have been reported that are made up of lists of marker genes indicative of the presence a given immune cell population. The majority of these gene signatures have been defined through analysis of isolated blood cells. However, blood cells do not reflect the differentiation or activation state of similar cells within tissues, including tumors, and consequently markers derived from blood cells do not necessarily transfer well to tissues. To address this issue, we generated a set of immune gene signatures derived directly from tissue transcriptomics data using a network-based deconvolution approach. We define markers for seven immune cell types, collectively named ImSig, and demonstrate how these markers can be used for the quantitative estimation of the immune cell content of tumor and nontumor tissue samples. The utility of ImSig is demonstrated through the stratification of melanoma patients into subgroups of prognostic significance and the identification of immune cells with the use of single-cell RNA-sequencing data derived from tumors. Use of ImSig is facilitated by an R package (imsig). Cancer Immunol Res; 6(11); 1388-400. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30266715     DOI: 10.1158/2326-6066.CIR-18-0342

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  56 in total

1.  A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer.

Authors:  Rachel L Stewart; Katherine L Updike; Rachel E Factor; N Lynn Henry; Kenneth M Boucher; Philip S Bernard; Katherine E Varley
Journal:  Cancer Res       Date:  2019-05-02       Impact factor: 12.701

2.  IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer.

Authors:  Li-Teng Ong; Wee Chyan Lee; Shijun Ma; Gokce Oguz; Zhitong Niu; Yi Bao; Mubaraka Yusuf; Puay Leng Lee; Jian Yuan Goh; Panpan Wang; Kylie Su Mei Yong; Qingfeng Chen; Wenyu Wang; Adaikalavan Ramasamy; Dave S B Hoon; Henrik J Ditzel; Ern Yu Tan; Soo Chin Lee; Qiang Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-25       Impact factor: 12.779

3.  Tumor microbiome links cellular programs and immunity in pancreatic cancer.

Authors:  Bassel Ghaddar; Antara Biswas; Chris Harris; M Bishr Omary; Darren R Carpizo; Martin J Blaser; Subhajyoti De
Journal:  Cancer Cell       Date:  2022-10-10       Impact factor: 38.585

4.  Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.

Authors:  Jashodeep Datta; Anna Bianchi; Iago De Castro Silva; Nilesh U Deshpande; Long Long Cao; Siddharth Mehra; Samara Singh; Christine Rafie; Xiaodian Sun; Xi Chen; Xizi Dai; Antonio Colaprico; Prateek Sharma; Austin R Dosch; Asha Pillai; Peter J Hosein; Nagaraj S Nagathihalli; Krishna V Komanduri; Julie M Wilson; Yuguang Ban; Nipun B Merchant
Journal:  Oncogene       Date:  2022-06-14       Impact factor: 8.756

Review 5.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

6.  Unveiling the immune infiltrate modulation in cancer and response to immunotherapy by MIXTURE-an enhanced deconvolution method.

Authors:  Elmer A Fernández; Yamil D Mahmoud; Florencia Veigas; Darío Rocha; Matías Miranda; Joaquín Merlo; Mónica Balzarini; Hugo D Lujan; Gabriel A Rabinovich; María Romina Girotti
Journal:  Brief Bioinform       Date:  2021-07-20       Impact factor: 11.622

7.  Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma.

Authors:  Daniel P Regan; Lyndah Chow; Sunetra Das; Laurel Haines; Eric Palmer; Jade N Kurihara; Jonathan W Coy; Alissa Mathias; Douglas H Thamm; Daniel L Gustafson; Steven W Dow
Journal:  Clin Cancer Res       Date:  2022-02-15       Impact factor: 13.801

Review 8.  Tumor immune microenvironment in head and neck cancers.

Authors:  Samantha M Y Chen; Alexandra L Krinsky; Rachel A Woolaver; Xiaoguang Wang; Zhangguo Chen; Jing H Wang
Journal:  Mol Carcinog       Date:  2020-02-03       Impact factor: 4.784

9.  Knowledge-based classification of fine-grained immune cell types in single-cell RNA-Seq data.

Authors:  Xuan Liu; Sara J C Gosline; Lance T Pflieger; Pierre Wallet; Archana Iyer; Justin Guinney; Andrea H Bild; Jeffrey T Chang
Journal:  Brief Bioinform       Date:  2021-09-02       Impact factor: 11.622

10.  Clinical Significance and Systematic Expression Analysis of the Thyroid Receptor Interacting Protein 13 (TRIP13) as Human Gliomas Biomarker.

Authors:  Ssu-Han Chen; Hong-Han Lin; Yao-Feng Li; Wen-Chiuan Tsai; Dueng-Yuan Hueng
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.